As of 2024-12-14, the Intrinsic Value of Harmony Biosciences Holdings Inc (HRMY) is
205.30 USD. This HRMY valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 32.39 USD, the upside of Harmony Biosciences Holdings Inc is
533.80%.
The range of the Intrinsic Value is 170.11 - 235.88 USD
205.30 USD
Intrinsic Value
HRMY Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(7,070.07) - (404.79) |
(744.26) |
-2397.8% |
| DCF (Growth 10y) |
(434.72) - (6,949.55) |
(769.78) |
-2476.6% |
| DCF (EBITDA 5y) |
170.11 - 235.88 |
205.30 |
533.8% |
| DCF (EBITDA 10y) |
382.39 - 648.83 |
510.76 |
1476.9% |
| Fair Value |
53.75 - 53.75 |
53.75 |
65.96% |
| P/E |
33.71 - 87.31 |
55.70 |
72.0% |
| EV/EBITDA |
31.07 - 134.07 |
81.34 |
151.1% |
| EPV |
25.01 - 40.33 |
32.67 |
0.9% |
| DDM - Stable |
25.73 - 449.22 |
237.48 |
633.2% |
| DDM - Multi |
122.12 - 1,694.36 |
229.94 |
609.9% |
HRMY Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,847.20 |
| Beta |
1.28 |
| Outstanding shares (mil) |
57.03 |
| Enterprise Value (mil) |
1,642.68 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.14% |
| Cost of Debt |
9.28% |
| WACC |
7.23% |